Pharmaceuticals
DrinkAid Marks Its Third Anniversary with an Exclusive Partnership with Singapore's Top Artistic Talent -- Tobyato, Jaeyelle, and JONT
SINGAPORE, Oct. 3, 2023 /PRNewswire/ -- DrinkAid, Singapore's pioneering health supplement brand that alleviates the side effects of alcohol, marks its third anniversary with an exclusive partnership withSingapore's top artistic talent — Tobyato, Jaeyelle, and JONT. The limited edition boxes, r...
2023-10-03 09:00
2280
Cambrex Completes $38 Million Capacity Expansion in High Point, North Carolina
EAST RUTHERFORD, N.J, Oct. 2, 2023 /PRNewswire/ -- Cambrex today announced the completion of its$38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility inHigh Point, North Carolina. This expansion doubles the facility's manufacturing capa...
2023-10-02 20:51
1549
China Review Studio and Chinese Red Cross Foundation Release "Generation Vax" Documentary for Broadcast Internationally
The documentary outlines China's contribution to vaccine science, research, and production since the COVID-19 pandemic and includes a call for science and infectious disease research to be borderless. BEIJING, Oct. 2, 2023 /PRNewswire/ -- China Review Studio, in collaboration with Chinese R...
2023-10-02 15:00
1597
MedAlliance Acquired by Cordis for USD 1.135 Billion
GENEVA, Oct. 2, 2023 /PRNewswire/ -- Swiss-based medical technology company MedAlliance has been acquired by Cordis for a 2022 investment of$35M and a 2023 upfront closing payment of$200M, together with regulatory achievement milestones of up to$125M and commercial milestones of up to $775M throu...
2023-10-02 11:44
2135
Rimegepant is Now Available in Hong Kong, the First Market in Asia, for Migraine Management
HONG KONG, Sept. 29, 2023 /PRNewswire/ -- Pfizer announced the availability of Rimegepant inHong Kong, the first market in Asia, a calcitonin gene-related peptide (CGRP) receptor antagonist for migraine management.[1],[2] There are approximately 12.5% of people living with migraine inHong Kong[3]...
2023-09-29 17:03
2550
Ascletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure
HANGZHOU and SHAOXING, China, Sept. 29, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces positive interim data from the Phase IIb expansion cohort (the "Expansion Cohort") of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) for functional cure of ch...
2023-09-29 08:10
2176
Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
82.4% of patients without prior CAR-T achieving Complete Response (CR) or better ROCKVILLE, Md. and SUZHOU, China, Sept. 29, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-qualit...
2023-09-29 08:00
2247
ALR Technologies Announces Patent Grant for Predictive A1C and Successful Results from Singapore General Hospital-led Study
SINGAPORE, Sept. 28, 2023 /PRNewswire/ -- ALR Technologies SG Ltd. ("ALRT" or the "Company") (OTCQB: ALRTF), a diabetes management company, announces the patent application titledMethod and System of Monitoring a Diabetes Treatment Plan("Predictive A1c") has been granted in Singapore and has rec...
2023-09-28 20:28
5059
Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting
SHANGHAI and HONG KONG, Sept. 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for canc...
2023-09-28 08:30
1684
Everest Medicines Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients
SHANGHAI, Sept. 28, 2023 /PRNewswire/ -- Everest Medicines
2023-09-28 07:38
1673
Besins Healthcare Unveils State-of-the-Art Hormone Factory in Muel, Spain, Amplifying Global Production Capabilities by 30%
"A Milestone in European Pharmaceutical Manufacturing": Besins Healthcare Debuts Pioneering Plant to Address Soaring Global Demand for Hormones and to Fortify Europe's Medical Sovereignty MONACO, Sept. 27, 2023 /PRNewswire/ -- Besins Healthcare, a global lead in Women's and Men's Reproductive He...
2023-09-27 15:56
1494
HRH Princess Astrid of Belgium visits Telix's New European Manufacturing Facility in Brussels South
MELBOURNE, Australia and LIEGE, Belgium, Sept. 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has welcomed Her Royal Highness,Princess Astrid, Princess of Belgium to Telix Manufacturing Solutions (TMS), the Company's recently inaugurated production facility,...
2023-09-27 12:00
1889
'Bayer For Her' Supporting 365 Days Conversations of Care to More Women in Asia
* Bridging the gap on lack of discussion amongst Asian women on their health concerns this World Contraception Day (WCD) SINGAPORE, Sept. 27, 2023 /PRNewswire/ -- Bayer Pharmaceuticals Division inAsia/Pacific announced today in conjunction with World Contraception Day, the inception of its 'Bay...
2023-09-27 10:00
1925
Latest Updates of Viva's Portfolio Companies
HONG KONG, Sept. 26, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the su...
2023-09-26 21:06
1505
YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
GAITHERSBURG, Md., Sept. 26, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...
2023-09-26 20:30
1390
Ascletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
--Based on prespecified interim analysis condition, 120 patients are likely to lead sufficient events for interim analysis of progression-free survival (PFS) HANGZHOU and SHAOXING, China, Sept. 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the completion o...
2023-09-26 08:10
1755
"Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery"
SHENZHEN, China, Sept. 25, 2023 /PRNewswire/ -- On September 15, "Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery" successfully kicked off. This marks the first time in recent years that the Company has organized an event specifically focused on pharmaceutical R&D innovation. The...
2023-09-25 15:31
1725
Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology
CASTRES, France and CAMBRIDGE, England, Sept. 25, 2023 /PRNewswire/ -- Pierre Fabre Laboratories and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets. ...
2023-09-25 15:00
1278
AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate®) First-in-Class Candidate for the Treatment of Intermediate Dry AMD
SHANGHAI, Sept. 25, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychi...
2023-09-25 09:00
2113
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
SHANGHAI, Sept. 25, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody independently developed by the company, in combination with drugs...
2023-09-25 07:41
1680
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 320 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Huawei Launching the All-Scenario Smart Telecom Power Solutions
2024-05-11 17:52
9673
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
5856
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
5506
Sobha Developers bring to Singapore an Exclusive Dubai Property Showcase
2024-05-11 17:48
4495
